Hepatitis C infection rates have been increasing in drug market harness – hepati
China is one of high incidence of viral hepatitis, the annual incidence of 200 million new cases of acute hepatitis in 50% of hepatitis, hepatitis B, 20% ~ 25%, hepatitis C accounts for 5% to 10%. China is a big country of hepatitis B, hepatitis B has always been "special treatment": routine physical examination, must submit two pairs of semi-hepatitis B, hepatitis B to the public early detection. Hepatitis B, "close relative" of hepatitis C has not attracted enough attention. It is reported that China's hepatitis C incidence and mortality rates increase rapidly, growing danger. 2009, the number of reported incidence is more than 6 times in 2003 the mortality rate jumped to fifth in infectious diseases. 80% of acute hepatitis C patients with no symptoms, up to 50-85% of acute patients will become chronic hepatitis C ,20-30 years, some chronic patients unconsciously develop into severe cirrhosis, and even liver cancer .
Currently no hepatitis C vaccine Although hepatitis C is necessary to prevent the public aware of the disease, but the general public on hepatitis C prevention methods, treatments are still errors. Recent survey of the medical profession, the public has a misunderstanding about Bacheng that hepatitis C have vaccination. Some people mistakenly believe that the Hepatitis B vaccine will be able to play against all types of hepatitis, there were two pairs that make up half of the examination of Hepatitis B, you can find all types of hepatitis, this is wrong. So far against the hepatitis C virus, the only effective approach is to do high-risk groups early detection of hepatitis C antibodies, early detection and aggressive treatment of disease.
The rapid development of anti-hepatitis C drug market
The world's leading pharmaceutical and medical health research and consulting firm Decision Resources, one of DecisionResources analysis of hepatitis C virus therapy market will grow in the next 10 years, nearly 5-fold, from 2007 to about 2 billion U.S. dollars 2017 more than 10 billion U.S. dollars, covering the United States, France, Germany, Italy, Spain, Britain and Japan.
2006, the world's anti-hepatitis drug market is about 4.5 billion to 48 billion by 2012 to 100 billion U.S. dollars; which, by the new and old drugs interferon and ribavirin will be composed of compound came out top . However, Interferon / Ribavirin Compound expensive, therefore, the domestic resistance to hepatitis C drug is still cheap ephedrine-based. Chinese and foreign pharmaceutical companies with greater strength
hepatitis C drug market Pharmaceutical manufacturers have recognized the hepatitis C market, there are still a lot of unmet need, and there is considerable commercial potential, therefore, the market has been the treatment of infectious diseases, drug development in recent years, the most active areas of .
DecisionResources company executives, MD, John? Lebbos said: "Hepatitis C virus is relatively still a need to develop a larger market, it has a complex epidemiology and infection in patients with multiple chronic elderly population in the next 10 During the year, is expected that the infected people will become increasingly showing characteristics of late infectious complications, such as cirrhosis. Because less than half of the patients currently using pegylated interferon and ribavirin pharmaceutical treatment can be cured, while also show considerable side effects, drug developers are still very large market space to provide a more secure and more effective treatments. "
Medicine is today the main drug treatment of viral hepatitis, many of which have been developed as a medicinal compound anti-hepatitis drug formulations.
Silymarin preparations at home and abroad for nearly half a century of market history. Clinical studies confirmed that silymarin on patients with chronic hepatitis Liver better protection for the liver. It is estimated that silymarin preparations in China domestic market sales of about 300 million ~ 400 million yuan; the actual occurrence of another drug acid derivatives, licorice, licorice as the world's main producing area in China, thus Licorice acid derivatives as the unique effect of anti- chronic hepatitis drugs headed varieties, with sales of anti-hepatitis Chinese domestic market accounted for 12%.
The e-commerce company in China offers quality products such as china XDECTM ECU , CRI-1001 Tester, and more. For more , please visit repair test equipment suppliers today!
Processing your request, Please wait....
